15 Best Biotech Penny Stocks to Invest in Right Now

6. Matinas BioPharma Holdings, Inc. (NYSE:MTNB)

Year-to-Date Return: 243.14%  

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) is a clinical-stage biopharmaceutical company developing oral anti-infective therapies using its proprietary lipid nanocrystal (LNC) platform. Its lead candidate, MAT2203, an oral formulation of amphotericin B, is advancing toward Phase 3 trials for invasive fungal infections such as aspergillosis and cryptococcosis. MAT2203 has shown promise in compassionate use cases, including reversing renal toxicity in patients previously treated with intravenous amphotericin B. Another pipeline asset, MAT2501, is an oral formulation of amikacin.

Recent developments as of September 2025 highlight strategic and operational shifts. The company made leadership changes, adding experienced biotech executives to its Board, and raised approximately $3.3 million through preferred stock and warrant sales. However, setbacks include the termination of global partnership negotiations for MAT2203 in 2024 and an 80% workforce reduction, with product development paused to preserve cash. The business is exploring strategic alternatives, including potential partnerships, sales, or restructuring options.

Despite challenges, Matinas BioPharma Holdings, Inc. (NYSE:MTNB) continues research collaborations leveraging its LNC platform with organizations such as BioNTech and Genentech, aiming to develop new drug formulations and delivery methods. While there are no recent approvals or pivotal trial readouts, the firm remains focused on restructuring and resource management. Its core asset, MAT2203, remains central to future growth, with Phase 3 trial progression expected to be a critical validation point for the oral antifungal therapy.